Imfinzi Shows Promise In Treating Gastric Cancer

AstraZeneca PLC had good news to share on Friday. The company reported that its Imfinzi medicine is working well in phase three trials for gastric and gastroesophageal junction cancers. This news comes from a planned interim analysis.

The drug company said their drug Imfinzi improved results significantly in patients with certain types of stomach and esophageal cancer. The drug was used alongside a standard chemotherapy called FLOT. The results were a big improvement when compared to just using the chemotherapy alone. This is good news for patients who have these types of cancers.

FLOT is a standard way to treat cancer. FLOT uses four chemotherapy drugs. The drugs are fluorouracil, leucovorin, oxaliplatin, and docetaxel.

Adding durvalumab to FLOT chemotherapy and surgery showed a rise in pathologic complete response, according to results. Josep Tabernero, head of the Medical Oncology Department at Vall d'Hebron University Hospital and principal investigator of the Matterhorn trial, said it was an encouraging early sign that the regimen might provide long-term benefits as pathologic complete response has been linked to event-free and overall survival across multiple settings.

AstraZeneca reported that the trial will proceed as scheduled. They will assess early feasibility studies and overall survival.

On Friday, shares of the company in Cambridge, England went down by 0.9%. They closed at 11,568.45 pence in London.

Heather Rydings writes news about economics for the Alliance News.

Send your comments and questions to [email protected].

The year is 2023 and Alliance News Ltd owns the copyright. No one else can use their content without permission. It's important to respect copyright laws and not steal other people's hard work. Always ask for permission before using someone else's work.